Pyrazolone formyl peptide 2 receptor agonists

A compound of formula I

• or a pharmaceutically acceptable salt thereof, wherein
• R1 is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, cycloalkyl, (Ar1)alkyl, or Ar1;
• Ar1 is cycloalkyl, piperidinyl, phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, or quinoxalinyl and, is substituted with 0-2 R5a and 0-2 R5b;
• R2 is alkyl or haloalkyl;
• R3 is phenyl or pyridinyl, and is substituted with 1 R3a and 0-2 R3b;
• R3a is halo, alkyl, haloalkyl, alkoxy, deuteroalkoxy, haloalkoxy, or cycloalkyl substituent in the para-position with respect to the pyrazol-3-one moiety;
• R3b is halo, alkyl, hydroxy, or haloalkyl;
• or R3a and the adjacent R3b, together with the two carbon atoms they are attached to, form a 3-6 membered heterocycle comprising carbon atoms and 1-3 heteroatoms selected from N, NH, O, S, and substituted with 0-3 halo, hydroxy, alkyl, haloalkyl, or alkoxycarbonyl;
• R4 is phenyl or pyridinyl, and is substituted with 1 R4a and 0-2 R4b;
• R4a is halo, alkyl, cycloalkyl, haloalkyl, alkoxy, haloalkoxy, or pyrazolyl substituent in the para-position with respect to the amide moiety;
• R4b is halo or haloalkyl;
• R5a and R5b are independently cyano, halo, alkyl, haloalkyl, alkoxyalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkoxy, hydroxyalkoxy, haloalkoxy, hydroxyhaloalkoxy, hydroxyalkoxyalkoxy, alkylsulfonylalkoxy, carboxamide, alkoxycarbonyl, alkylaminoalkyl, alkoxycarbonylalkoxy, hydroxyalkylcycloalkylalkyl, alkylsulfonyl, aminocarbonylalkyl, —NR7R8, cycloalkyl substituted with 0-3 halo, hydroxy, alkyl, or alkoxy, phenyl substituted with 0-3 halo, hydroxy, or alkyl, 4-8 membered heterocyclyl comprising carbon atoms and 1-3 heteroatoms selected from N, NH, O, S, and substituted with 0-3 halo, alkyl, hydroxyalkyl, haloalkyl, alkoxycarbonyl, or alkylsulfonyl, heterocyclyloxy, heterocyclylalkyl, or heterocyclylalkoxy, wherein the heterocyclyl moiety of the heterocyclyloxy, heterocyclylalkyl, and heterocyclylalkoxy comprises 4-8 carbon atoms and 1-3 heteroatoms selected from N, NH, O, S, and substituted with 0-3 halo, hydroxy, hydroxyalkyl, alkyl, or haloalkyl;
• R6 is hydrogen or lower alkyl;
• R7 and R8 are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, halohydroxyalkyl, alkoxyalkyl, aminocarbonylalkyl, alkylsulfonyl;
• alkylaminocarbonylalkyl, cycloalkylaminocarbonylalkyl, cycloalkylalkyl, hydroxycycloalkylalkyl, hydroxyalkylcycloalkylalkyl, cycloalkylalkyl, cycloalkyl, wherein each cycloalkyl is substituted with 0-3 halo, hydroxy, or alkyl, or hydroxyalkyl, or 5-8 membered heterocyclyl comprising carbon atoms and 1-3 heteroatoms selected from N, NH, O, S, and substituted with 0-3 halo, hydroxy, alkyl, haloalkyl, or alkoxycarbonyl;
• or R7 and R8, together with the nitrogen to which they are attached, form a 5-12 membered heterocycle comprising carbon atoms and 0-3 additional heteroatoms selected from N, NH, O, S, and substituted with 0-5 halo, hydroxy, alkyl, alkoxy, oxo, haloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, alkylsulfonyl, alkylsulfonylalkyl, aminocarbonyl, or alkoxycarbonyl;
• provided that when Ar1 is triazolyl, oxadiazolyl, or thiadiazolyl, Ar1 is substituted with 0-1 R5a and 0-1 R5b.